Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer

Journal of Clinical Oncology

Volumn 22, Issue 19, 2004, Pages 3893-3901

  Keller, Alan M ^a   Mennel, Robert G ^a   Georgoulias, Vassilis A ^a   Nabholtz, Jean Marc ^a   Erazo, Aura ^a   Lluch, Anna ^a   Vogel, Charles L ^a   Kaufmann, Manfred ^a   von Minckwitz, Gunther ^a   Henderson, I Craig ^a   Mellars, Lillian ^a   Alland, Leila ^a   Tendler, Craig ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MITOMYCIN C; NAVELBINE; VINBLASTINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DRUG DERIVATIVE; LIPOSOME; MITOMYCIN; TAXANE; TAXOID;

ALOPECIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT FAILURE; VOMITING; ADULT; AGED; BREAST TUMOR; COMPARATIVE STUDY; DRUG RESISTANCE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SALVAGE THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; SALVAGE THERAPY; TAXOIDS; VINBLASTINE;

EID: 5444251223     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.157     Document Type: Article

References (16)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
2. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998
3. Data on file. Schering-Plough Research Institute, Kenilworth, NJ
4. Symon Z, Peyser A, Tzemach D, et al: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86:72-78, 1999
5. Gabizon A, Martin F: Polyethylene glycolcoated (pegylated) liposomal doxorubicin: Rationale for use in solid tumours. Drugs 54:15-21, 1997
6. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322, 2001
7. Ranson MR, Carmichael J, O'Byrne K, et al: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 15:3185-3191, 1997
8. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
9. Kalofonos HP, Onyenadum A, Kosmas C, et al: Mitomycin C and vinblastine in anthracycline-resistant metastatic breast cancer: A phase II study. Tumori 87:394-397, 2001
10. Zelek L, Barthier S, Riofrio M, et al: Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267-2272, 2001
11. Fleming I, Cooper J, Henson D, et al: AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven, 1997
12. Yates JW, Chalmer B, McKegney FP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45: 2220-2224, 1980
13. EORTC Quality of Life Study Group: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (ed Version 3.0), 1995
14. Gelber R, Cole B, Gelber S, et al: Comparing treatments using quality-adjusted survival: The Q-TWiST method. Am Stat 49:161-169, 1995
15. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567-2574, 1995
16. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999